{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Status:
Investigational
Source:
NCT00055926: Phase 1 Interventional Completed Breast Cancer
(2003)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
CP 724714 is an orally bioavailable, quinazoline-based, selective small molecule inhibitor of the HER2/erbB2 receptor tyrosine kinase. The compound could have particular potential in the treatment of women with metastatic breast cancer, of which 25-30% over express HER2/erbB2. CP 724714 was in preclinical development with Pfizer.
Status:
Investigational
Source:
NCT00348699: Phase 1 Interventional Completed Male Breast Cancer
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Kirax Corporation (formerly Tigris Pharmaceuticals) was developing AFP-464, a lysyl prodrug of aminoflavone for the treatment of solid tumours. AFP-464 is an antitumor agent which was in phase II clinical trials, acts against estrogen-positive breast cancer (ER+). AFP-464, has a unique mechanism of action by activating aryl hydrocarbon receptor (AhR) signaling pathway. Preclinical studies into AFP-464's mechanism of action have shown that AFP-464 is converted to metabolites, which bind covalently to DNA, resulting in p53 activation and apoptosis. AFP-464 has shown a unique pattern of growth inhibitory activity in the NCI's 60 tumor cell line screen, with breast, ovarian, lung and renal tumor cell lines exhibiting particular sensitivity to the compound. In vivo anti-tumor activity of AFP-464 has been demonstrated in several xenograft studies in mice bearing renal and breast cancer. Preclinical studies have shown that tumors (breast, ovarian, pancreatic and renal) with AhR localized in the cytoplasm are very sensitive to AFP-464 while those with AhR localized in the nucleus are more resistant. AFP-464 was being studied by Tigris Pharmaceuticals in a randomized Phase 2 clinical trial with ER-positive breast cancer patients. However, AFP-464 development was discontinued.
Status:
Investigational
Source:
NCT00612118: Phase 2 Interventional Completed Allergic Rhinitis
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
GSK-256066 is a PDE4B inhibitor which was developed by GlaxoSmithKline and tested in phase II of clinical trials for the treatment of COPD, Asthma and Seasonal allergic rhinitis. According to the GSK pipeline, development of GSK-256066 was terminated. There are studies that describes the possibility of repurposing of the drug as antitrypanosomal agents, because it inhibits PDEB1 of Trypanosoma brucei.
Status:
Investigational
Source:
JAN:HYOSCYAMINE METHYLBROMIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Hyoscyamine methylbromide, a muscarinic acetylcholine receptor antagonist, was studied as an antispasmodic.
Status:
Investigational
Source:
NCT02798627: Phase 2 Interventional Completed Cocaine Use Disorder
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
NS-2359, an orally active, triple monoamine reuptake inhibitor that inhibits the reuptake of dopamine, noradrenaline and serotonin, is being developed by Saniona and the Treatment Research Center (TRC) at the University of Pennsylvania for the treatment of Cocaine abuse. NS-2359’s pharmacological profile means that it may be able to reduce cocaine withdrawal symptoms, reduce cocaine craving and reduce cocaine-induced euphoria. Previously NS-2359 was in clinical trials for the treatment of attention-deficit hyperactivity disorder and major depressive disorder, but development was discontinued due to lack of effectiveness.
Status:
Investigational
Source:
NCT03397134: Phase 3 Interventional Completed Negative Symptoms of Schizophrenia
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
CYR-101 (MIN-101) is a cyclic amide derivative that has high equipotent affinities for 5-HT2A and sigma-2 receptors (Ki of 7.53 nM and 8.19 nM for 5-HT2A and sigma-2, respectively). MIN-101 also shows binding affinity for a1-adrenergic receptors but low or no affinity for muscarinic, cholinergic, and
histaminergic receptors. MIN-101 demonstrated statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients. The drug is in phase II clinical trials for the treatment of Schizophrenia.
Status:
Investigational
Source:
NCT00954538: Phase 1 Interventional Completed Alzheimer's Disease
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01416623: Phase 1 Interventional Terminated Advanced Solid Cancer
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Henatinib was developed as a multitargeted tyrosine kinase inhibitor with antitumor activities. Henatinib is an endothelial growth factor receptor type 2 (VEGFR2) antagonist. The drug participated in phase I clinical trial to evaluate the safety and tolerability in patients with advanced solid malignancies, however, the study was terminated. The current development status is unknown.
Status:
Investigational
Source:
NCT00387413: Phase 1 Interventional Completed Hyperalgesia
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Status:
Investigational
Source:
NCT01564459: Phase 2 Interventional Completed Diabetic Neuropathy, Painful
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Filorexant (MK-6096) is a novel, structurally distinct dual orexin receptor antagonist, conclusively validates orexin signalling mechanism as a specific and effective target for the treatment of insomnia and potentially other disorders in which sleep/wake dysregulation occurs. Also, it is being investigated as a possible agent against diabetic neuropathies, major depressive disorder and for the a migraine prophylaxis. Detected adverse events are: sleep-onset paralysis, excessive daytime sleepiness. As of May 2015, filorexant is no longer listed on Merck's online development pipeline.
